Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

Autor: Aruna, Das Pradhan, Robert J, Glynn, Jean-Charles, Fruchart, Jean G, MacFadyen, Elaine S, Zaharris, Brendan M, Everett, Stuart E, Campbell, Ryu, Oshima, Pierre, Amarenco, Dirk J, Blom, Eliot A, Brinton, Robert H, Eckel, Marshall B, Elam, João S, Felicio, Henry N, Ginsberg, Assen, Goudev, Shun, Ishibashi, Jacob, Joseph, Tatsuhiko, Kodama, Wolfgang, Koenig, Lawrence A, Leiter, Alberto J, Lorenzatti, Boris, Mankovsky, Nikolaus, Marx, Børge G, Nordestgaard, Dénes, Páll, Kausik K, Ray, Raul D, Santos, Handrean, Soran, Andrey, Susekov, Michal, Tendera, Koutaro, Yokote, Nina P, Paynter, Julie E, Buring, Peter, Libby, Paul M, Ridker, Maureen, McClelland

Publikováno v: Das Pradhan, A, Glynn, R J, Fruchart, J C, MacFadyen, J G, Zaharris, E S, Everett, B M, Campbell, S E, Oshima, R, Amarenco, P, Blom, D J, Brinton, E A, Eckel, R H, Elam, M B, Felicio, J S, Ginsberg, H N, Goudev, A, Ishibashi, S, Joseph, J, Kodama, T, Koenig, W, Leiter, L A, Lorenzatti, A J, Mankovsky, B, Marx, N, Nordestgaard, B G, Páll, D, Ray, K K, Santos, R D, Soran, H, Susekov, A, Tendera, M, Yokote, K, Paynter, N P, Buring, J E, Libby, P & Ridker, P M 2022, ' Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. ', New England Journal of Medicine, vol. 387, no. 21, pp. 1923-1934 . https://doi.org/10.1056/NEJMoa2210645

Background High triglyceride levels are associated with increased cardiovascular risk, but whether reductions in these levels would lower the incidence of cardiovascular events is uncertain. Pemafibrate, a selective peroxisome proliferator-activated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73f084970bad344fb37812ba1fc7407c
https://pubmed.ncbi.nlm.nih.gov/36342123

Comparison of the Lipid-Lowering Effects of Pitavastatin 4 mg Versus Pravastatin 40 mg in Adults With Primary Hyperlipidemia or Mixed (Combined) Dyslipidemia: A Phase IV, Prospective, US, Multicenter, Randomized, Double-blind, Superiority Trial

Autor: Michael H. Davidson, Craig A. Sponseller, Stuart E. Campbell, Roger E. Morgan, Vladimir A. Kryzhanovski

Publikováno v: Clinical Therapeutics. 36:1211-1222

Results from a Phase III, European, non-inferiority trial in elderly (age ≥65 years) patients with primary hyperlipidemia or mixed (combined) dyslipidemia demonstrated significantly greater reductions in LDL-C for pitavastatin versus pravastatin ac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62f158ecde2390610b21cef2946750d7
https://doi.org/10.1016/j.clinthera.2014.06.009

Effects of Steady-State Lopinavir/Ritonavir on the Pharmacokinetics of Pitavastatin in Healthy Adult Volunteers

Autor: Matthew M. Medlock, Kazuhito Suehira, Stuart E. Campbell, Craig A. Sponseller, Christine Y. Yu, Roger E. Morgan

Publikováno v: JAIDS Journal of Acquired Immune Deficiency Syndromes. 60:158-164

Objectives Pitavastatin, a statin recently approved in the United States, has a potential benefit of reduced risk of cytochrome P450 (CYP)-mediated drug-drug interaction due to minimal metabolism by the CYP system. The primary objective was to invest

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29b853cc862c4015206a889abe071678
https://doi.org/10.1097/qai.0b013e318251addb

Pitavastatin 4 mg Is Superior to Pravastatin 40 mg in LDL-C Reduction: Results from PREVAIL US Trial in Primary Hyperlipidemia or Mixed Dyslipidemia†

Autor: Roger E. Morgan, Michael H. Davidson, Craig A. Sponseller, Christine Y. Yu, Stuart E. Campbell, Vladimir A. Kryzhanovski

Publikováno v: Journal of Clinical Lipidology. 6:280-282

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c1f8b35e6bdb56c5740bcbf9a83eb7cd
https://doi.org/10.1016/j.jacl.2012.04.059

Pitavastatin 4 Mg Significantly Reduces LDL-P and Increases HDL Size Compared with Pravastatin 40 mg: Results from PREVAIL US

Autor: Roger E. Morgan, Stuart E. Campbell, Christine Y. Yu, Michael H. Davidson, Craig A. Sponseller

Publikováno v: Journal of Clinical Lipidology. 6:288-289

s 289 12 in lipoprotein particle concentrations and size. The median change in LDL particle concentration (LDL-P) was 2505.0 nmol/L for pitavastatin and 2376.0 nmol/L for pravastatin (treatment difference 5 2127.0 nmol/L; P , .001), with no significa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c5db4bb72c3d10ab824e7f83ba87950c
https://doi.org/10.1016/j.jacl.2012.04.068